TY - JOUR
T1 - Antinociception induced by rosuvastatin in murine neuropathic pain
AU - Miranda, Hugo F.
AU - Sierralta, Fernando
AU - Aranda, Nicolas
AU - Poblete, Paula
AU - Castillo, Rodrigo L.
AU - Noriega, Viviana
AU - Prieto, Juan Carlos
N1 - Funding Information:
Partially supported by project UNAB DI-1349-16/R.
Publisher Copyright:
© 2018 Institute of Pharmacology, Polish Academy of Sciences
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Background: Neuropathic pain, and subsequent hypernociception, can be induced in mice by paclitaxel (PTX) administration and partial sciatic nerve ligation (PSNL). Its pharmacotherapy has been a clinical challenge, due to a lack of effective treatment. In two models of mouse neuropathic pain (PTX and PSNL) the antinociception induced by rosuvastatin and the participation of proinflammatory biomarkers, interleukin (IL)- 1β TBARS and glutathione were evaluated. Methods: A dose–response curve for rosuvastatin ip was obtained on cold plate, hot plate and Von Frey assays. Changes on spinal cord levels of IL-1β glutathione and lipid peroxidation were measured at 7 and 14 days in PTX and PSNL murine models. Results: PTX or PSNL were able to induce in mice peripheral neuropathy with hypernociception, either to 7 and 14 days. Rosuvastatin induced a dose dependent antinociception in hot plate, cold plate and Von Frey assays. The increased levels of IL-1β or TBARS induced by pretreatment with PTX or PSNL were reduced by rosuvastatin. The reduction of spinal cord glutathione, by PTX or PSNL, expressed as the ratio GSH/GSSG, were increased significantly in animals pretreated with rosuvastatin. The anti-inflammatory properties of statins could underlie their beneficial effects on neuropathic pain by reduction of proinflammatory biomarkers and activation of glia. Conclusion: The findings of this study suggest a potential usefulness of rosuvastatin in the treatment of neuropathic pain.
AB - Background: Neuropathic pain, and subsequent hypernociception, can be induced in mice by paclitaxel (PTX) administration and partial sciatic nerve ligation (PSNL). Its pharmacotherapy has been a clinical challenge, due to a lack of effective treatment. In two models of mouse neuropathic pain (PTX and PSNL) the antinociception induced by rosuvastatin and the participation of proinflammatory biomarkers, interleukin (IL)- 1β TBARS and glutathione were evaluated. Methods: A dose–response curve for rosuvastatin ip was obtained on cold plate, hot plate and Von Frey assays. Changes on spinal cord levels of IL-1β glutathione and lipid peroxidation were measured at 7 and 14 days in PTX and PSNL murine models. Results: PTX or PSNL were able to induce in mice peripheral neuropathy with hypernociception, either to 7 and 14 days. Rosuvastatin induced a dose dependent antinociception in hot plate, cold plate and Von Frey assays. The increased levels of IL-1β or TBARS induced by pretreatment with PTX or PSNL were reduced by rosuvastatin. The reduction of spinal cord glutathione, by PTX or PSNL, expressed as the ratio GSH/GSSG, were increased significantly in animals pretreated with rosuvastatin. The anti-inflammatory properties of statins could underlie their beneficial effects on neuropathic pain by reduction of proinflammatory biomarkers and activation of glia. Conclusion: The findings of this study suggest a potential usefulness of rosuvastatin in the treatment of neuropathic pain.
KW - Antinociception
KW - Neuropathy
KW - Rosuvastatin
KW - Spinal cord biomarkers
UR - http://www.scopus.com/inward/record.url?scp=85045249401&partnerID=8YFLogxK
U2 - 10.1016/j.pharep.2017.11.012
DO - 10.1016/j.pharep.2017.11.012
M3 - Article
AN - SCOPUS:85045249401
SN - 1734-1140
VL - 70
SP - 503
EP - 508
JO - Pharmacological Reports
JF - Pharmacological Reports
IS - 3
ER -